Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Tercica Ipsen |
---|---|
Information provided by: | Tercica |
ClinicalTrials.gov Identifier: | NCT00774930 |
The purpose of this study is to determine whether monthly injections of Somatuline Depot are effective and safe in controlling diarrhea and flushing in patients with carcinoid syndrome.
Condition | Intervention | Phase |
---|---|---|
Carcinoid Syndrome |
Drug: lanreotide Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomized Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome |
Estimated Enrollment: | 100 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Somatuline Depot 120 mg
|
Drug: lanreotide
subcutaneous injection, 120 mg, q28d
|
2: Placebo Comparator
Placebo
|
Drug: placebo
inactive substance
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Rodney van Syoc | 650-238-1598 | rodney.vanSyoc@tercica.com |
Contact: Katrin Chondros | 650-238-1565 | katrin.chondros@tercica.com |
United States, Oregon | |
Providence Portland Medical Center | Recruiting |
Portland, Oregon, United States, 97213 | |
Contact: Katie Strauss 503-215-2619 | |
Principal Investigator: Todd Crocenzi, MD | |
United States, Virginia | |
Eastern Virginia Medical School | Recruiting |
Norfolk, Virginia, United States, 23510 | |
Contact: Patricia Barlow 757-446-5293 | |
Principal Investigator: Aaron Vinik, MD |
Study Chair: | Edda Gomez-Panzani, M.D. | Tercica |
Responsible Party: | Tercica ( Edda Gomez-Panzani, MD ) |
Study ID Numbers: | TR321 |
Study First Received: | October 15, 2008 |
Last Updated: | March 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00774930 History of Changes |
Health Authority: | United States: Food and Drug Administration |
carcinoid tumor |
Carcinoid Syndrome Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Serotonin Syndrome Poisoning Angiopeptin Disorders of Environmental Origin Cardiovascular Agents Malignant Carcinoid Syndrome Hormones Somatostatin |
Neuroendocrine Tumors Carcinoma Neuroectodermal Tumors Lanreotide Drug Toxicity Neoplasms, Germ Cell and Embryonal Neuroepithelioma Carcinoid Tumor Adenocarcinoma Neoplasms, Glandular and Epithelial |
Antineoplastic Agents Physiological Effects of Drugs Neoplasms, Nerve Tissue Hormones, Hormone Substitutes, and Hormone Antagonists Disorders of Environmental Origin Angiopeptin Hormones Pathologic Processes Neoplasms, Germ Cell and Embryonal Syndrome Therapeutic Uses Neoplasms by Histologic Type Disease Serotonin Syndrome |
Poisoning Malignant Carcinoid Syndrome Cardiovascular Agents Somatostatin Pharmacologic Actions Carcinoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Lanreotide Drug Toxicity Carcinoid Tumor Adenocarcinoma Neoplasms, Glandular and Epithelial |